Treatment with the commercially available anti-MUC1 antibody GP1.4 resulted in the inhibition of proliferation and migration of pancreatic cancer cells by activating the internalization of EGFR which leads to sequestration of surface receptors and repression of ERK phosphorylation [19]. The gene discussed is EGFR; the disease is pancreatic neoplasm.